Stuart Hughes

Company: Pathios Therapeutics

Job title: Chief Executive Officer

Seminars:

Closing Panel: The Future of Innate Immune Checkpoints & Activation 2:30 pm

Delving into the horizons of homing of innate cells and reprograming of the tumor microenvironment Discussing novel checkpoint inhibitors Analysing the various immunotherapy approaches discussed & beyond Updates on clinical trials for immunotherapies In vitro models and discovery technologies for innate cell-based therapies New methodologies of analyzing innate immune cells in the tumor microenvironment (scRNAseq,…Read more

day: Innate Immune Checkpoints & Activation Pre-Focus Day

Low pH-Induced Polarization of Human Macrophages Toward a Pro- Tumorigenic, Wound repair Phenotype is Fully Reversed by Small Molecule Inhibitors of GPR65: Implications for Cancer Immunotherapy 10:30 am

The extracellular microenvironment of solid tumors is typically much more acidic than surrounding tissue This acidic environment has a profound effect on macrophages and other innate immune cells, leading to a pronounced polarization of these cells toward a protumorigenic or wound repair phenotype Pathios proprietary small molecule GPR65 inhibitors are able to fully counteract this…Read more

day: Innate Immune Checkpoints & Activation Pre-Focus Day